Discovery & Development

The FDA says it wants to phase out mandatory animal testing requirements for drug approval. What comes next?

As biologics become more complex, mass spec becomes more indispensable than ever in the drug developer’s toolbox.

Eli Lilly and Purdue University strengthen their ongoing drug discovery collaboration with further initiatives.

How new structural insights captured in high-resolution images could fuel next-gen therapies for TB.

We ask an expert about best practices for working with these complicated therapies.

Let us not forget the important role of academic spinouts in innovating across the modalities.

Researchers use AI to produce synthetic pharmacokinetic data.

Can digital tools help lower the carbon footprint of a clinical trial? First, we need more data.

Galimedix Therapeutics explains how small molecule drug candidates could provide new treatments for Alzheimer’s disease and beyond.

We speak with an advocate for alternative drug testing methods about the challenges that lie ahead.